MedTrace Logo

Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months

NCT02017808 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2014-12-03

No results posted yet for this study

Summary

This is a prospective, observational, single-blinded, longitudinal, 24-month OCT study of the evolution of axonal loss, as evidenced by loss of RNFLT and TMV, in RRMS patients treated with GA and in healthy controls.

Conditions

Sponsors & Collaborators

  • Teva Pharmaceuticals USA

    collaborator INDUSTRY

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Robert Zivadinov, MD, PhD · SUNY University at Buffalo

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02017808 on ClinicalTrials.gov